Particularly, CEA and C153 showed no diagnostic value when distinguishing stage I + II BC patients from the benign group (P>0.05), possible due to their limited sensitivity and specificity during the early stages of disease (42–45). The gene discussed is CEACAM5; the disease is breast cancer.